Companies:
49,811
Total Market Cap:
139341229653344.19
Global Rank
#10098
Country Rank
#37
Market Cap
925.15 M
Price
14.92
Change (%)
0.77%
Volume
100,034
GH Research PLC's latest marketcap:
925.15 M
As of 07/05/2025, GH Research PLC's market capitalization has reached $925.15 M. According to our data, GH Research PLC is the 10098th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 925.15 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -42,107,000 |
| Shares Out | 62.03 M |
| EPS (ttm) | -0.79 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/08/2025 |
Market Cap Chart
Data Updated: 07/05/2025
GH Research PLC's yearly market capitalization.
GH Research PLC has seen its market value drop from $1.21 B to $925.15 M since 2021, representing a total decrease of 23.77% and an annual compound decline rate (CAGR) of 7.44%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $925.15 M | 154.02% | 10098 |
| 12/31/2024 | $364.2 M | 20.71% | 15102 |
| 12/29/2023 | $301.72 M | -40.33% | 16430 |
| 12/30/2022 | $505.64 M | -58.34% | 12179 |
| 12/31/2021 | $1.21 B | 8337 |
Company Profile
About GH Research PLC
GH Research PLC, along with its subsidiary, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for depression and related disorders in the United States.
Key Product Candidates
- GH001 – An inhalable mebufotenin product candidate currently in:
- Phase 2b clinical trial for treatment-resistant depression.
- Phase 2a clinical trials for bipolar II disorder with major depressive episodes and postpartum depression in female patients.
- GH002 – An intravenous mebufotenin product candidate in Phase 1 clinical trials for psychiatric and neurological disorders, targeting healthy volunteers.
Company Background
Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Frequently Asked Questions
-
What is GH Research PLC's (GHRS) current market cap?As of 07/05/2025, GH Research PLC (including the parent company, if applicable) has an estimated market capitalization of $925.15 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does GH Research PLC (GHRS) rank globally by market cap?GH Research PLC global market capitalization ranking is approximately 10098 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.